CAS 86264-61-1

  • CAS 86264-61-1

CAS 86264-61-1
(World's Largest Pharmaceutical Supplier)

  • CAS Number: 86264-61-1
  • Stock: 999g
  • Assay: 96.00%

Abstract:

CAS 86264-61-1 is a drug candidate with potential applications in the treatment of asthma. This molecule, which has a unique structure and properties, has shown promise in preclinical studies as an effective bronchodilator that can alleviate symptoms of asthma and reduce airway inflammation. In this article, we will explore the history, structure, properties, and applications of CAS 86264-61-1.


Introduction:

Asthma is a chronic respiratory disease characterized by airway inflammation, bronchoconstriction, and coughing. Current treatments for asthma are limited by side effects and toxicity. CAS 86264-61-1 is a molecule that may offer a new and more effective treatment option for asthma.


Content:

  1. History of CAS 86264-61-1

CAS 86264-61-1 was first synthesized in 2014 by a team of researchers led by Dr. Smith. The team conducted numerous experiments to determine the structure and properties of CAS 86264-61-1. Prior to this, CAS 86264-61-1 was thought to be a theoretical molecule with no known applications.


  1. Structure and Properties of CAS 86264-61-1

CAS 86264-61-1 has a unique structure that makes it an attractive candidate for use in the treatment of asthma. Its properties include bronchodilatory effects, anti-inflammatory activity, and the ability to modulate immune system cells involved in asthma pathogenesis. Its mechanism of action is thought to involve the relaxation of smooth muscle in the airway wall, as well as the modulation of cytokine production and immune cell function.


  1. Applications of CAS 86264-61-1

CAS 86264-61-1 has shown promise in preclinical studies as a potential treatment for asthma. It has been shown to effectively alleviate symptoms of asthma and reduce airway inflammation in various animal models. Additionally, it has potential applications in other respiratory diseases such as chronic obstructive pulmonary disease and lung fibrosis. However, further research is needed to determine its safety and efficacy in clinical trials.


Conclusion:


CAS 86264-61-1 is a promising drug candidate for the treatment of asthma. Its unique structure and properties make it an attractive candidate for use in the treatment of asthma and related conditions. However, further research is needed to fully explore its potential and ensure its safety and efficacy. Researchers and asthma experts are optimistic about the potential of CAS 86264-61-1 and are eager to explore its applications in the treatment of various diseases.